DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TECHNETIUM TC 99M SESTAMIBI

« Back to Dashboard

Clinical Trials for Technetium Tc 99m Sestamibi

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00162045	A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects	Completed	Lantheus Medical Imaging	Phase 1/Phase 2	The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
NCT00162071	A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging	Terminated	Forest Laboratories	Phase 2	The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
NCT00560495	Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	Withdrawn	National Cancer Institute (NCI)	Phase 1	RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00560495	Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	Withdrawn	Roswell Park Cancer Institute	Phase 1	RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00767468	Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis	Terminated	National Cancer Institute (NCI)	Phase 1	RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.

Clinical Trial Conditions for Technetium Tc 99m Sestamibi

Condition Name

Condition Name for Technetium Tc 99m Sestamibi
Intervention	Trials
Constipation-predominant Irritable Bowel Syndrome	1
Cardiovascular Disease	1
Short Bowel Syndrome	1
Lung Cancer	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Technetium Tc 99m Sestamibi
Intervention	Trials
Syndrome	2
Liver Neoplasms	1
Cardiovascular Diseases	1
Carcinoma, Hepatocellular	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Technetium Tc 99m Sestamibi

Trials by Country

Trials by Country for Technetium Tc 99m Sestamibi
Location	Trials
United States	12
Taiwan	1
Canada	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Technetium Tc 99m Sestamibi
Location	Trials
Minnesota	2
New York	2
North Carolina	1
Wisconsin	1
Washington	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Technetium Tc 99m Sestamibi

Clinical Trial Phase

Clinical Trial Phase for Technetium Tc 99m Sestamibi
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2
Phase 1/Phase 2	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Technetium Tc 99m Sestamibi
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Withdrawn	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Technetium Tc 99m Sestamibi

Sponsor Name

Sponsor Name for Technetium Tc 99m Sestamibi
Sponsor	Trials
National Cancer Institute (NCI)	2
Mayo Clinic	2
Forest Laboratories	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Technetium Tc 99m Sestamibi
Sponsor	Trials
NIH	4
Other	4
Industry	2

Export unavailable in trial.
Subscribe for complete access.